April 24th Mesoblast reports 83% survival in...

April 24^th Mesoblast reports 83% survival in ventilator-dependent COVID-19 patients with moderate/severe acute respiratory distress syndrome (ARDS) treated with two infusions of Mesoblast’s allogeneic cell therapy remestemcel-L within the first five days under emergency compassionate use at New York City’s Mt Sinai hospital during the period March-April 2020.

What ever happened to the 9 Covid-19 survivors who walked free and clear from Mt Sinai hospital? How are they faring now? After almost 6 months do they exhibit any of the so called long term legacy effects of Covid?

July 6^th Mesoblast reports that an expanded access protocol (EAP) was initiated for the compassionate use of the allogeneic mesenchymal stem cell (MSC) product candidate remestemcel-L in the treatment of COVID-19 infected children with cardiovascular and other complications of multisystem inflammatory syndrome (MIS-C)?

From the MUSC Shawn Jenkins Children’s Hospital in Charleston, South Carolina there was the amazing First in Nation treatment and early recovery story (Aug 25^th) of a 4 year old boy (J.K Griffin); How is he faring now? The story also mentions at least 7 other children having been similarly treated. Was their recovery similar and how are they faring now?

I DON’T KNOW; but I’m thinking even in the absence of a control there should be a good level of patient follow-up and data record available right now that wouldn’t hurt in providing a strong supporting indication as to the effectiveness of remestemel-L as a treatment; or not!